DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Saturday 25 June 2016

Sreenivasa Reddy Mundla


Sreenivasa Reddy

 Sreenivasa Mundla Reddy

Managing Director at Sreeni Labs Private Limited

Sreeni Labs Private Limited
Road No:12, Plot No:24,25,26
  • IDA, Nacharam
    Hyderabad, 500076
    Telangana State, India

links
https://in.linkedin.com/in/sreenivasa-reddy-10b5876
https://www.facebook.com/sreenivasa.mundla
https://www.researchgate.net/profile/Sreenivasa_Mundla/info
mundlasr@hotmail.com
Ph:+91-9866092626

Sreenivasa Mundla Reddy




M. Sreenivasa Reddy obtained Ph.D from University of Hyderabad under the direction Prof Professor Goverdhan Mehta in 1992. From 1992-1994, he was a post doctoral fellow at University of Wisconsin in Professor Jame Cook's lab. From 1994 to 2000,  worked at Chemical process R&D at Procter & Gamble Pharmaceuticle (P&G). From 2001 to 2007 worked at Global Chemical Process R&D at Eli Lilly and Company in Indianapolis. 

In 2007  resigned to his  job and found Sreeni Labs based in Hyderabad and working with various global customers and solving various challenging synthesis problems.
 
The main strength of Sreeni Labs is in the design, development of a novel chemical route and its development into a robust process followed by production of quality product from 100 grams to 100s of kg scale.
 

They have helped number of customers by successfully developing highly economical simple chemistry routes to number of products that were made by Suzuki coupling. they are able to shorten the route by drastically reducing number of steps, avoiding use of palladium & expensive ligands. they always use readily available or easy to prepare starting materials in their design of synthetic routes.

Sreeni Labs is Looking for any potential opportunities where people need development of cost effective scalable routes followed by quick scale up to produce quality products in the pharmaceutical & specialty chemicals area. They have flexible business model that will be in sink with customers. One can test their abilities & capabilities by giving PO based projects

Experience







Founder & Managing Director

Sreeni Labs Private Limited
– Present (8 years 11 months)
Sreeni Labs Profile
Sreeni Labs Profile
View On SlideShare









Principal Research Scientist

Eli Lilly and Company
– (6 years 6 months)











Senior Research Scientist

Procter & Gamble
– (6 years 8 months)




Education











University of Hyderabad

Doctor of Philosophy (Ph.D.)




January 22, 2015 ·
With Sreenivasa Mundla, Narahara sastry, Ram Kishan Rao, Jagadeesh Bharatam, Jagadish Gunjur and Jagadish Bharatham.

 

 

 





See presentation below


Sreeni Labs Profile from Sreenivasa Reddy 
CLICK CURSOR TO VIEW




PUBLICATIONS





 Read at http://pharmacology.case.edu/department/faculty/primary/pages/Palczewski/articles/2015/Mol%20Pharmacol-2015-Zhang-477-91.pdf


Patents by Inventor Sreenivasa Reddy Mundla
  • TGF-? inhibitors
    Patent number: 7872020
    Abstract: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro -4H-pyrrolo[1,2-b]pyrazole monohydrate.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: January 18, 2011
    Assignee: Eli Lilly and Company
    Inventor: Sreenivasa Reddy Mundla
  • TGF-BETA INHIBITORS
    Publication number: 20100120854
    Abstract: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate.
    Type: Application
    Filed: June 29, 2006
    Publication date: May 13, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventor: Sreenivasa Reddy Mundla
  • Process for making 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives
    Patent number: 6066740
    Abstract: The present invention provides a process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydroyrimidine derivatives by preparing the corresponding activated 2-thio-subsituted-2-derivative in a two-step, one-pot procedure and by further reacting yields this isolated derivative with the appropriate amine or its salts in the presence of a proton source. The present process allows for the preparation of 2-amino-2-imidazolines, quanidines, and 2-amino-3,4,5,6-tetrahydropyrimidines under reaction conditions that eliminate the need for lengthy, costly, or multiple low yielding steps, and highly toxic reactants. This process allows for improved yields and product purity and provides additional synthetic flexibility.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: May 23, 2000
    Assignee: The Procter & Gamble Company
    Inventors: Michael Selden Godlewski, Sean Rees Klopfenstein, Sreenivasa Reddy Mundla, William Lee Seibel, Randy Stuart Muth


TGF-β inhibitors
US 7872020 B2
 Sreenivasa Reddy Mundla
The present invention provides 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl) -5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate, i.e., Formula I.

Figure US07872020-20110118-C00002

 EXAMPLE 1 Preparation of 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H -pyrrolo[1,2-b]pyrazole monohydrate

Figure US07872020-20110118-C00008

  Galunisertib

1H NMR (CDCl3): δ=9.0 ppm (d, 4.4 Hz, 1H); 8.23-8.19 ppm (m, 2H); 8.315 ppm (dd, 1.9 Hz, 8.9 Hz, 1H); 7.455 ppm (d, 4.4 Hz, 1H); 7.364 ppm (t, 7.7 Hz, 1H); 7.086 ppm (d, 8.0 Hz, 1H); 6.969 ppm (d, 7.7 Hz, 1H); 6.022 ppm (m, 1H); 5.497 ppm (m, 1H); 4.419 ppm (t, 7.3 Hz, 2H); 2.999 ppm (m, 2H); 2.770 ppm (p, 7.2 Hz, 7.4 Hz, 2H); 2.306 ppm (s, 3H); 1.817 ppm (m, 2H). MS ES+: 370.2; Exact: 369.16



ABOVE MOLECULE IS
https://newdrugapprovals.org/2016/05/04/galunisertib/
Galunisertib
Phase III
LY-2157299
CAS No.700874-72-2


Sreeni labs









////////
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)